The efficacy and safety of capecitabine plus bevacizumab combination as first-line treatment in elderly metastatic colorectal cancer patients

• Published in: Clinical & translational oncology Vol. 18; no. 6; pp. 617 - 624
• Main Authors: Ozcelik, M., Odabas, H., Ercelep, O., Yuksel, S., Mert, A. G., Aydin, D., Surmeli, H., Isik, D., Isik, S., Oyman, A., Oven Ustaalioglu, B. B., Aliustaoglu, M., Gumus, M.
• Format: Journal Article
• Language: English
• Published: Milan Springer Milan 01-06-2016
• Subjects: Adenocarcinoma - drug therapy; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Bevacizumab - administration & dosage; Capecitabine - administration & dosage; Colorectal Neoplasms - drug therapy; Colorectal Neoplasms - mortality; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Male; Medicine; Medicine & Public Health; Oncology; Research Article; Retrospective Studies; Older patients; Capecitabine; Elderly; Metastatic colorectal cancer; Bevacizumab
• ISSN: 1699-048X; 1699-3055
• DOI: 10.1007/s12094-015-1408-6

Aim
The optimal treatment in older persons with metastatic colorectal cancer (mCRC) is complicated by a lack of general agreement. The aim of this study was to evaluate the activity of bevacizumab plus capecitabine combination in elderly mCRC patients who were not suitable for chemotherapy with irinotecan and oxaliplatin-containing regimens.
Materials and methods
Seventy years and older patients with metastatic colorectal carcinoma were included in this retrospective study. Bevacizumab was administered at a dose of 7.5 mg/kg on day 1 as an intravenous (IV) infusion over 30–90 min every 21 days, and capecitabine was prescribed at 1000 mg/m
2
twice daily on days 1–14 of the same 21-day schedule.
Results
Eighty-two consecutive patients (47 men, 35 women) were included in the study. The mean age was 75.5 (SD 3.9, range 70–87). Half of the patients were older than 75 years. There were 55 patients (67.1 %) with a good Eastern Cooperative Oncology Group (ECOG) performance status (PS: 0–1) and the remaining 27 patients (32.9 %) had a poor ECOG performance status (PS: 2). With a median follow-up period of 18.5 months, the median progression-free survival (PFS) was 10 months (95 % CI, 7.8–12.1) and the median OS was 25 months (95 % CI, 18.6–31.3). The main toxicities recorded were non-hematological. Thirty-one patients (37 %) experienced grade 3/4 adverse events, the most common being hand–foot syndrome (9.8 %). No fatal toxicity resulting from this regimen was recorded.
Conclusions
Considering the toxicity profile and survival outcomes, the combination regimen of capecitabine and bevacizumab is a potentially feasible treatment option in elderly mCRC patients.